Most Insiders Tend To Buy Stock At The Right Time And Here Is Some Proof

Let’s now turn our focus on Coffee Holding Co. Inc. (NASDAQ:JVA), a wholesale coffee dealer and roaster that saw one of its most important figures acquire stock last week. Andrew Gordon, who has acted as Chief Executive Officer, President, Treasurer, and Director since 1997, and Chief Financial Officer since 2004, reported the acquisition of 5,000 shares at prices ranging from $4.05 to $4.11, all of which are owned directly by A. Gordon Family Ventures LLC. Following the transaction, the executive’s affiliate company owns 233,183 shares. A little more than a month ago, Coffee Holding Co. released its financial results for its fiscal third quarter that ended July 31, posting net sales of $27.0 million compared to $26.6 million reported a year ago. This marked the company’s third straight quarter with year-over-year sales growth in spite of the challenging coffee market and commodity pricing. However, the company’s stock performance continued its downward trend, which appears to be turning around only now. The shares of Coffee Holding have lost nearly 20% since the beginning of the year, which might point to the fact that the executive is buying shares on weakness. Ken Griffin’s Citadel Investment Group acquired a 10,907-share stake in Coffee Holding Co. Inc. (NASDAQ:JVA) during the second quarter.

Finally, we will take a look into the insider trading activity at Spark Therapeutics Inc. (NASDAQ:ONCE). Director Steven M. Altschuler acquired a new stake of 5,000 shares last Wednesday at a weighted average price of $49.11. Surprisingly, this purchase was made just a few days before the company presented additional data from its Phase 3 pivotal trial, including continued durability data from a previous Phase 1 study of SPK-RPE65. This represents the company’s lead product candidate for the treatment of RPE65-mediated inherited retinal dystrophies (IRDs). The freshly-released positive top-line results from the Phase 3 clinical trial for the treatment of rare blinding conditions seems to have pleased both investors and its future patients. The shares of Spark advanced by more than 4% in today’s pre-market trading session, but are now down by 1.18% today and are over 2% in the red year-to-date. Baker Bros. Advisors, founded by Julian and Felix Baker, represents the largest shareholder of Spark Therapeutics Inc. (NASDAQ:ONCE) within our database, owning 1.26 million shares.

Disclosure: None